☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Malignant Pleural Mesothelioma
BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelio...
June 3, 2021
ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelio...
May 28, 2021
Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma
February 16, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.